Copyright Reports & Markets. All rights reserved.

Global Peripherally Acting Anti-Obesity Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Prescription Drugs
    • 1.3.3 Non-prescription Drugs
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital Pharmacies
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Online Pharmacies
  • 1.5 Global Peripherally Acting Anti-Obesity Drug Market Size & Forecast
    • 1.5.1 Global Peripherally Acting Anti-Obesity Drug Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Peripherally Acting Anti-Obesity Drug Sales Quantity (2021-2032)
    • 1.5.3 Global Peripherally Acting Anti-Obesity Drug Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk A/S
    • 2.1.1 Novo Nordisk A/S Details
    • 2.1.2 Novo Nordisk A/S Major Business
    • 2.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novo Nordisk A/S Recent Developments/Updates
  • 2.2 Pfizer Inc.
    • 2.2.1 Pfizer Inc. Details
    • 2.2.2 Pfizer Inc. Major Business
    • 2.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Pfizer Inc. Recent Developments/Updates
  • 2.3 Boehringer Ingelheim International GmbH
    • 2.3.1 Boehringer Ingelheim International GmbH Details
    • 2.3.2 Boehringer Ingelheim International GmbH Major Business
    • 2.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
  • 2.4 KVK Tech Inc.
    • 2.4.1 KVK Tech Inc. Details
    • 2.4.2 KVK Tech Inc. Major Business
    • 2.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.4.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 KVK Tech Inc. Recent Developments/Updates
  • 2.5 Gelesis Holdings
    • 2.5.1 Gelesis Holdings Details
    • 2.5.2 Gelesis Holdings Major Business
    • 2.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.5.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Gelesis Holdings Recent Developments/Updates
  • 2.6 Vivus LLC.
    • 2.6.1 Vivus LLC. Details
    • 2.6.2 Vivus LLC. Major Business
    • 2.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.6.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Vivus LLC. Recent Developments/Updates
  • 2.7 Currax Pharmaceuticals LLC
    • 2.7.1 Currax Pharmaceuticals LLC Details
    • 2.7.2 Currax Pharmaceuticals LLC Major Business
    • 2.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.7.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Currax Pharmaceuticals LLC Recent Developments/Updates
  • 2.8 GlaxoSmithKline plc
    • 2.8.1 GlaxoSmithKline plc Details
    • 2.8.2 GlaxoSmithKline plc Major Business
    • 2.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.8.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 GlaxoSmithKline plc Recent Developments/Updates
  • 2.9 CHEPLAPHARM Arzneimittel GmbH
    • 2.9.1 CHEPLAPHARM Arzneimittel GmbH Details
    • 2.9.2 CHEPLAPHARM Arzneimittel GmbH Major Business
    • 2.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
  • 2.10 Rhythm Pharmaceuticals
    • 2.10.1 Rhythm Pharmaceuticals Details
    • 2.10.2 Rhythm Pharmaceuticals Major Business
    • 2.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
    • 2.10.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Rhythm Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Peripherally Acting Anti-Obesity Drug by Manufacturer

  • 3.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturer (2021-2026)
  • 3.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Peripherally Acting Anti-Obesity Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Peripherally Acting Anti-Obesity Drug Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Peripherally Acting Anti-Obesity Drug Manufacturer Market Share in 2025
  • 3.5 Peripherally Acting Anti-Obesity Drug Market: Overall Company Footprint Analysis
    • 3.5.1 Peripherally Acting Anti-Obesity Drug Market: Region Footprint
    • 3.5.2 Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
    • 3.5.3 Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Peripherally Acting Anti-Obesity Drug Market Size by Region
    • 4.1.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2021-2032)
    • 4.1.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Region (2021-2032)
  • 4.2 North America Peripherally Acting Anti-Obesity Drug Consumption Value (2021-2032)
  • 4.3 Europe Peripherally Acting Anti-Obesity Drug Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value (2021-2032)
  • 4.5 South America Peripherally Acting Anti-Obesity Drug Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2021-2032)
  • 5.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type (2021-2032)
  • 5.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2021-2032)
  • 6.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application (2021-2032)
  • 6.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2021-2032)
  • 7.2 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2021-2032)
  • 7.3 North America Peripherally Acting Anti-Obesity Drug Market Size by Country
    • 7.3.1 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2021-2032)
  • 8.2 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2021-2032)
  • 8.3 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country
    • 8.3.1 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size by Region
    • 9.3.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2021-2032)
  • 10.2 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2021-2032)
  • 10.3 South America Peripherally Acting Anti-Obesity Drug Market Size by Country
    • 10.3.1 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Peripherally Acting Anti-Obesity Drug Market Size by Country
    • 11.3.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Peripherally Acting Anti-Obesity Drug Market Drivers
  • 12.2 Peripherally Acting Anti-Obesity Drug Market Restraints
  • 12.3 Peripherally Acting Anti-Obesity Drug Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Peripherally Acting Anti-Obesity Drug and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Peripherally Acting Anti-Obesity Drug
  • 13.3 Peripherally Acting Anti-Obesity Drug Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Peripherally Acting Anti-Obesity Drug Typical Distributors
  • 14.3 Peripherally Acting Anti-Obesity Drug Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Peripherally Acting Anti-Obesity Drug market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    A Peripherally Acting Anti-Obesity Drug is a medication designed to treat obesity by acting on the peripheral nervous system or other systems in the body. These drugs target various mechanisms involved in appetite regulation, metabolism, and fat absorption to aid in weight loss.
    This report is a detailed and comprehensive analysis for global Peripherally Acting Anti-Obesity Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Peripherally Acting Anti-Obesity Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Peripherally Acting Anti-Obesity Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Peripherally Acting Anti-Obesity Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Peripherally Acting Anti-Obesity Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Peripherally Acting Anti-Obesity Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Peripherally Acting Anti-Obesity Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk A/S, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech Inc., Gelesis Holdings, Vivus LLC., Currax Pharmaceuticals LLC, GlaxoSmithKline plc, CHEPLAPHARM Arzneimittel GmbH, Rhythm Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Peripherally Acting Anti-Obesity Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Prescription Drugs
    Non-prescription Drugs
    Market segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies
    Major players covered
    Novo Nordisk A/S
    Pfizer Inc.
    Boehringer Ingelheim International GmbH
    KVK Tech Inc.
    Gelesis Holdings
    Vivus LLC.
    Currax Pharmaceuticals LLC
    GlaxoSmithKline plc
    CHEPLAPHARM Arzneimittel GmbH
    Rhythm Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Peripherally Acting Anti-Obesity Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Peripherally Acting Anti-Obesity Drug, with price, sales quantity, revenue, and global market share of Peripherally Acting Anti-Obesity Drug from 2021 to 2026.
    Chapter 3, the Peripherally Acting Anti-Obesity Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Peripherally Acting Anti-Obesity Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Peripherally Acting Anti-Obesity Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Peripherally Acting Anti-Obesity Drug.
    Chapter 14 and 15, to describe Peripherally Acting Anti-Obesity Drug sales channel, distributors, customers, research findings and conclusion.

    Buy now